Krystal Biotech, Inc. KRYS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s total liabilities & equity?
- Krystal Biotech, Inc. (KRYS) reported total liabilities & equity of $1.4B in Q1 2026.
- How has Krystal Biotech, Inc.'s total liabilities & equity changed year-over-year?
- Krystal Biotech, Inc.'s total liabilities & equity increased by 30.0% year-over-year, from $1.07B to $1.4B.
- What is the long-term trend for Krystal Biotech, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total liabilities & equity has grown at a 33.8% compound annual growth rate (CAGR), from $310.84M to $1.33B.
- What does total liabilities & equity mean?
- The total value of the company's assets, shown as the sum of its debt and equity.
- How do you interpret total liabilities & equity?
- Growth in this figure generally indicates the expansion of the company's asset base and operational scale.
- How does total liabilities & equity compare across companies?
- Used as a baseline for comparing the size and scale of companies within the same sector.